{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T15:13:49Z","timestamp":1791558829897,"version":"4.3.4"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Food and Drug Administration (FDA) of the U.S. Department of Health and Human Services"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>When using real-world data to construct an external comparator arm for a single-arm trial, there may be differences in how and when patients are assessed for disease between trial and real-world settings. Such differences can generate outcome measurement error when comparing time-to-event endpoints and lead to biased findings. Recent methods have been developed to mitigate measurement error bias in real-world endpoints; however, they rely on the existence of a validation sample, ie, data on a set of patients where both the \u201ctrue\u201d trial-like and \u201cmis-measured\u201d real-world measures are collected. We demonstrate how novel statistical methods can be leveraged as quantitative bias analyses (QBA) to contextualize real-world evidence findings when outcome measurement error is of concern, but validation samples are infeasible to collect. Quantitative bias analyses allow researchers to set plausible ranges for the amount of error when not directly measurable. We highlight how to conduct QBA with two recent methods, cumulative incidence curve correction and survival regression calibration, and illustrate how to generate plausible parameter values through simulation. We provide an illustrative QBA example in a cohort of real-world patients with newly diagnosed multiple myeloma and provide practical guidance to apply QBA for outcome measurement error and interpret results.<\/jats:p>","DOI":"10.1093\/aje\/kwag027","type":"journal-article","created":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T12:49:41Z","timestamp":1770209381000},"page":"2476-2483","source":"Crossref","is-referenced-by-count":1,"title":["Quantitative bias analyses to address measurement error in time-to-event endpoints"],"prefix":"10.1093","volume":"195","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2522-6623","authenticated-orcid":false,"given":"Benjamin","family":"Ackerman","sequence":"first","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan W","family":"Gan","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youyi","family":"Zhang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Hayden","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jocelyn R","family":"Wang","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig S","family":"Meyer","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juned","family":"Siddique","sequence":"additional","affiliation":[{"name":"Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University , Chicago, IL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1108-0689","authenticated-orcid":false,"given":"Jennifer L","family":"Lund","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill , Chapel Hill, NC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janick","family":"Weberpals","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2575-467X","authenticated-orcid":false,"given":"Sebastian","family":"Schneeweiss","sequence":"additional","affiliation":[{"name":"Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women\u2019s Hospital, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9204-7177","authenticated-orcid":false,"given":"Til","family":"St\u00fcrmer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology, University of North Carolina at Chapel Hill , Chapel Hill, NC ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Roose","sequence":"additional","affiliation":[{"name":"Flatiron Health , New York, NY ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omar","family":"Nadeem","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Dana-Farber Cancer Institute, Harvard Medical School , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"Center for Multiple Myeloma, Massachusetts General Hospital Cancer Center , Boston, MA ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sikander","family":"Ailawadhi","sequence":"additional","affiliation":[{"name":"Department of Hematology, Mayo Clinic , Jacksonville, FL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smith","family":"Giri","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham , Birmingham, AL ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hester","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Brayer","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashita S","family":"Batavia","sequence":"additional","affiliation":[{"name":"Johnson & Johnson , Raritan, NJ ,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"issue":"6","key":"2026090221222085200_ref1","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1002\/cpt.3443","article-title":"External controls to study treatment effects in rare diseases: challenges and future directions","volume":"116","author":"Weberpals","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"2026090221222085200_ref2","volume-title":"Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products","author":"Center for Drug Evaluation and Research","year":"2023"},{"key":"2026090221222085200_ref3","doi-asserted-by":"crossref","first-page":"1423493","DOI":"10.3389\/fdsfr.2024.1423493","article-title":"Measurement error and bias in real-world oncology endpoints when constructing external control arms","volume":"4","author":"Ackerman","year":"2024","journal-title":"Front Drug Saf Regul"},{"key":"2026090221222085200_ref4","doi-asserted-by":"crossref","DOI":"10.1201\/9781420010138","volume-title":"Measurement Error in Nonlinear Models","author":"Carroll","year":"2006"},{"issue":"1","key":"2026090221222085200_ref5","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/epirev\/mxab011","article-title":"The measurement error elephant in the room: challenges and solutions to measurement error in epidemiology","volume":"43","author":"Innes","year":"2021","journal-title":"Epidemiol Rev"},{"issue":"1","key":"2026090221222085200_ref6","doi-asserted-by":"publisher","first-page":"kxa052","DOI":"10.1093\/biostatistics\/kxaf052","article-title":"Risk functions with outcome measurement error","volume":"27","author":"Edwards","year":"2025","journal-title":"Biostatistics."},{"issue":"1","key":"2026090221222085200_ref7","doi-asserted-by":"publisher","DOI":"10.1515\/em-2025-0009","article-title":"Regression calibration for time-to-event outcomes: mitigating bias due to measurement error in real-world endpoints","volume":"14","author":"Ackerman","year":"2025","journal-title":"Epidemiologic Methods"},{"key":"2026090221222085200_ref8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinepi.2024.111507","article-title":"Quantitative bias analysis methods for summary-level epidemiologic data in the peer-reviewed literature: a systematic review","volume":"175","author":"Shi","year":"2024","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"2026090221222085200_ref9","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1093\/ije\/dyab061","article-title":"A systematic review of quantitative bias analysis applied to epidemiological research","volume":"50","author":"Petersen","year":"2021","journal-title":"Int J Epidemiol"},{"issue":"3","key":"2026090221222085200_ref10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/EDE.0000000000001600","article-title":"Opioid-related mortality in United States death certificate data: a quantitative bias analysis with expert elicitation of bias parameters","volume":"34","author":"Goldsmith","year":"2023","journal-title":"Epidemiology"},{"key":"2026090221222085200_ref11","volume-title":"Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products","author":"Center for Drug Evaluation and Research","year":"2025"},{"issue":"2","key":"2026090221222085200_ref12","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"8","key":"2026090221222085200_ref13","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Supplement 1","key":"2026090221222085200_ref14","doi-asserted-by":"publisher","first-page":"3763","DOI":"10.1182\/blood-2024-199224","article-title":"Design and methodological considerations for real world data-derived progression-free survival in multiple myeloma","volume":"144","author":"Wang","year":"2024","journal-title":"Blood."},{"issue":"5","key":"2026090221222085200_ref15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.9655","article-title":"Concordance of clinician-documented and imaging response in patients with stage IV non\u2013small cell lung cancer treated with first-line therapy","volume":"5","author":"Ma","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026090221222085200_ref16","doi-asserted-by":"crossref","first-page":"4460","DOI":"10.1111\/1475-6773.12872","article-title":"Development and validation of a high-quality composite real-world mortality endpoint","volume":"53","author":"Curtis","year":"2018","journal-title":"Health Serv Res"},{"key":"2026090221222085200_ref17","doi-asserted-by":"crossref","volume-title":"A Novel Methodology for Assessing Response to Lymphoma Treatment in Real-World Studies\u2014The Real-World Lugano (RWLUGANO) Study","author":"Swain","DOI":"10.1016\/j.jval.2024.03.2416"},{"issue":"1","key":"2026090221222085200_ref18","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s12874-021-01308-8","article-title":"IPDfromKM: reconstruct individual patient data from published Kaplan-Meier survival curves","volume":"21","author":"Liu","year":"2021","journal-title":"BMC Med Res Methodol"},{"issue":"11","key":"2026090221222085200_ref19","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/S1470-2045(21)00466-6","article-title":"Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial","volume":"22","author":"Facon","year":"2021","journal-title":"Lancet Oncol"},{"issue":"5","key":"2026090221222085200_ref20","doi-asserted-by":"publisher","DOI":"10.1002\/pds.5796","article-title":"Use of quantitative bias analysis to evaluate single-arm trials with real-world data external controls","volume":"33","author":"Gray","year":"2024","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"29","key":"2026090221222085200_ref21","doi-asserted-by":"crossref","first-page":"5738","DOI":"10.1002\/sim.9590","article-title":"A proper statistical inference framework to compare clinical trial and real-world progression-free survival data","volume":"41","author":"Zhu","year":"2022","journal-title":"Stat Med"}],"container-title":["American Journal of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/aje\/advance-article-pdf\/doi\/10.1093\/aje\/kwag027\/66792934\/kwag027.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/9\/2476\/66792934\/kwag027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/aje\/article-pdf\/195\/9\/2476\/66792934\/kwag027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:22:30Z","timestamp":1788398550000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/aje\/article\/195\/9\/2476\/8466094"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":21,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,2,6]]},"published-print":{"date-parts":[[2026,9,3]]}},"URL":"https:\/\/doi.org\/10.1093\/aje\/kwag027","relation":{},"ISSN":["0002-9262","1476-6256"],"issn-type":[{"value":"0002-9262","type":"print"},{"value":"1476-6256","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,2,6]]}}}